Literature DB >> 9449257

Therapeutic effects of water-soluble echinocandin compounds on Pneumocystis pneumonia in mice.

T Furuta1, H Muramatsu, A Fujie, S Fujihira, N R Abudullah, S Kojima.   

Abstract

The therapeutic effectiveness of water-soluble echinocandin compounds obtained from Coleophoma empetri F-11899, which has a strong inhibitory effect on the growth of fungi, was examined in nude mice with experimental Pneumocystis pneumonia. The studies demonstrated the potential usefulness of the compounds.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9449257      PMCID： PMC105452     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Treatment of Pneumocystis carinii pneumonia with 1,3-beta-glucan synthesis inhibitors.

Authors:  D M Schmatz; M A Romancheck; L A Pittarelli; R E Schwartz; R A Fromtling; K H Nollstadt; F L Vanmiddlesworth; K E Wilson; M J Turner
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

2.  Yeast glucan in the cyst wall of Pneumocystis carinii.

Authors:  Y Matsumoto; S Matsuda; T Tegoshi
Journal:  J Protozool       Date:  1989 Jan-Feb

3.  WF11899A, B and C, novel antifungal lipopeptides. I. Taxonomy, fermentation, isolation and physico-chemical properties.

Authors:  T Iwamoto; A Fujie; K Sakamoto; Y Tsurumi; N Shigematsu; M Yamashita; S Hashimoto; M Okuhara; M Kohsaka
Journal:  J Antibiot (Tokyo)       Date:  1994-10       Impact factor: 2.649

4.  Amplification of mitochondrial ribosomal RNA sequences from Pneumocystis carinii DNA of rat and human origin.

Authors:  A E Wakefield; F J Pixley; S Banerji; K Sinclair; R F Miller; E R Moxon; J M Hopkin
Journal:  Mol Biochem Parasitol       Date:  1990-11       Impact factor: 1.759

5.  Severe pulmonary pneumocystosis in simian acquired immunodeficiency syndrome induced by simian immunodeficiency virus: its characterization by the polymerase-chain-reaction method and failure of experimental transmission to immunodeficient animals.

Authors:  T Furuta; M Fujita; R Mukai; I Sakakibara; T Sata; K Miki; M Hayami; S Kojima; Y Yoshikawa
Journal:  Parasitol Res       Date:  1993       Impact factor: 2.289

6.  WF11899A, B and C, novel antifungal lipopeptides. II. Biological properties.

Authors:  T Iwamoto; A Fujie; K Nitta; S Hashimoto; M Okuhara; M Kohsaka
Journal:  J Antibiot (Tokyo)       Date:  1994-10       Impact factor: 2.649

7.  Pneumocystis carinii pneumonia in thoroughbred foals: identification of a genetically distinct organism by DNA amplification.

Authors:  S E Peters; A E Wakefield; K E Whitwell; J M Hopkin
Journal:  J Clin Microbiol       Date:  1994-01       Impact factor: 5.948

8.  Effect of T-cell transfer on Pneumocystis carinii infection in nude mice.

Authors:  T Furuta; K Ueda; S Kyuwa; K Fujiwara
Journal:  Jpn J Exp Med       Date:  1984-04

9.  Pneumocandins from Zalerion arboricola. IV. Biological evaluation of natural and semisynthetic pneumocandins for activity against Pneumocystis carinii and Candida species.

Authors:  D M Schmatz; G Abruzzo; M A Powles; D C McFadden; J M Balkovec; R M Black; K Nollstadt; K Bartizal
Journal:  J Antibiot (Tokyo)       Date:  1992-12       Impact factor: 2.649

10.  Antipneumocystis activity of water-soluble lipopeptide L-693,989 in rats.

Authors:  D M Schmatz; M A Powles; D C McFadden; L Pittarelli; J Balkovec; M Hammond; R Zambias; P Liberator; J Anderson
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191
  10 in total
  1 in total

1.  Prophylactic effect of FK463, a novel antifungal lipopeptide, against Pneumocystis carinii infection in mice.

Authors:  M Ito; R Nozu; T Kuramochi; N Eguchi; S Suzuki; K Hioki; T Itoh; F Ikeda
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.